Basics X4 Pharmaceuticals Inc Arsanis Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of monoclonal antibodies for the targeted immunotherapy of serious infections. IPO Date: May 13, 2022 Sector: Healthcare Industry: Biotech Market Cap: $6.56M Activated in VL: True Average Daily Range Avg Daily Range: $0.07 | 5.17% Avg Daily Range (30 D): $0.03 | 3.69% Avg Daily Range (90 D): $0.05 | 4.47% Institutional Daily Volume Avg Daily Volume: .55M Avg Daily Volume (30 D): .1M Avg Daily Volume (90 D): .46M Trade Size Avg Trade Size (Sh.): 230 Avg Trade Size (Sh.) (30 D): 421 Avg Trade Size (Sh.) (90 D): 300 Institutional Trades Total Inst.Trades: 10 Avg Inst. Trade: $.93M Avg Inst. Trade (30 D): $2.54M Avg Inst. Trade (90 D): $2.54M Avg Inst. Trade Volume: .18M Avg Inst. Trades (Per Day): 5 Market Closing Trades Avg Closing Trade: $.53M Avg Closing Trade (30 D): $M Avg Closing Trade (90 D): $M Avg Closing Volume: 142.9K         News Aug 14, 2024 @ 9:45 PM Actelis Networks Reports Q2 2024 Results: 372% Seq... Source: N/A Jul 11, 2024 @ 9:16 AM Why WD-40 Shares Are Trading Higher By Over 12%; H... Source: Avi Kapoor Jul 10, 2024 @ 8:06 PM Actelis Receives $260,000 Order for Major Mid-Atla... Source: Actelis Networks, Inc. Jun 28, 2024 @ 12:30 PM Actelis Receives Order from Major German Municipal... Source: Actelis Networks, Inc. Jun 27, 2024 @ 8:25 PM Actelis Continues to Expand International Footprin... Source: Actelis Networks, Inc. Financials   TTM Q4 2024 FY 2024 Basic EPS $-.85 $-.26 $-.85 Diluted EPS $-.85 $-.26 $-.85 Revenue $ 7.76M $ 1.06M $ 7.76M Gross Profit $ 4.27M $ .36M $ 4.27M Net Income / Loss $ -4.37M $ -1.8M $ -4.37M Operating Income / Loss $ -3.76M $ -1.64M $ -3.76M Cost of Revenue $ 3.49M $ .7M $ 3.49M Net Cash Flow $ -3.25M $ -.27M $ -3.25M PE Ratio     Splits Apr 19, 2023:   10:1 Mar 14, 2019:   6:1